Why GlaxoSmithKline’s 2017 Guidance Is Conservative

Assuming that Advair will face competition from a substitutable generic in the US by mid-2017, GSK guided for flat to a slight decline in Core EPS at constant exchange rates. The stock is trading at a discount to five years average historical P/E vs. peers and some potential source of earnings upside is expected in 2017.

Mylan launches generic Zovia in U.S.

Mylan has announced the launch of a generic version of Zovia , a pregnancy preventative, in the U.S. The product — Ethyniol Diacetate and Ethinyl Estradiol tablets — was found to be bioequivalent to Zovia, and subsidiary Jai Pharma got FDA approval for its abbreviated new drug application.